Skip to content
value.today

OS Therapies Inc

🇺🇸 Grasonville, Maryland, USABiotechnologyFounded 2018
Total raised
$9 M
2 rounds on record
Latest round
$7 M
Dec 2024
First round on record
Nov 2022
Today
Went public
See the company page

OS Therapies Inc is listed today as OS Therapies Incorporated: market value, financials and filings are on its company page.

Funding rounds

2 counted as startup funding, 7 other private sales on record. Open the number of investors for the round's details.

Funding rounds of OS Therapies Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2026$7 MPrivate placement after listing$2 to $10 million

OS Therapies Inc: Private sale, Oct 2026

Investors in this round

9 investors had bought by the notice of Oct 23, 2026: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $12 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$859,774
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Francis Knuettel II · Executive Officer · Chief Financial Officer
  • Kerry Clem · Executive Officer · Chief Commercial Officer
  • Paul A. Romness · Executive Officer, Director · Chairman, President and Chief Executive Officer
  • Robert G. Petit · Executive Officer · Chief Medical Officer and Chief Scientific Officer
  • Avril McKean Dieser · Director
  • Craig Eagle · Director
  • John Ciccio · Director
  • Olivier Jarry · Director
  • Theodore F. Search · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ceros Financial Services, Inc. (CRD 37869) · Rockville, MarylandSold in all US states

Signed by Francis Knuettel II, Chief Financial Officer. Source: SEC Form D, newest notice filed Oct 23, 2026. Read the notice at the SEC.

equity, optionsSEC
Aug 2026$5 MPrivate placement after listing$2 to $10 million

OS Therapies Inc: Private sale, Aug 2026

Investors in this round

10 investors had bought by the notice of Aug 25, 2026: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $10 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$500,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher P. Acevedo · Executive Officer · Chief Financial Officer
  • Paul A. Romness · Executive Officer, Director · Chairman, President and Chief Executive Officer
  • Robert G. Petit · Executive Officer · Chief Medical Officer and Chief Scientific Officer
  • Avril P. McKean Dieser · Director
  • Craig P. Eagle · Director
  • John P. Ciccio · Director
  • Olivier P. Jarry · Director
  • Theodore F. Search · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ceros Financial Services, Inc. (CRD 37869) · Rockville, MarylandSold in all US states

Signed by Christopher P. Acevedo, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 25, 2026. Read the notice at the SEC.

equity, debt, optionsSEC
Jun 2026$2 MPrivate placement after listingUnder $2 million

OS Therapies Inc: Private sale, Jun 2026

Investors in this round

1 investor had bought by the notice of Jul 16, 2026: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $9 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher P. Acevedo · Executive Officer · Chief Financial Officer
  • Paul A. Romness · Executive Officer, Director · Chairman, President and Chief Executive Officer
  • Robert G. Petit · Executive Officer · Chief Medical Officer and Chief Scientific Officer
  • Avril P. McKean Dieser · Director
  • Craig P. Eagle · Director
  • John P. Ciccio · Director
  • Olivier P. Jarry · Director
  • Theodore F. Search · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Christopher P. Acevedo, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 16, 2026. Read the notice at the SEC.

debt, optionsSEC
Mar 2026$2 MPrivate placement after listing$2 to $10 million

OS Therapies Inc: Private sale, Mar 2026

Investors in this round

9 investors had bought by the notice of Mar 6, 2026: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$140,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher P. Acevedo · Executive Officer · Chief Financial Officer
  • Paul A. Romness · Executive Officer, Director · Chairman, President and Chief Executive Officer
  • Robert G. Petit · Executive Officer · Chief Medical Officer and Chief Scientific Officer
  • Avril P. McKean Dieser · Director
  • John P. Ciccio · Director
  • Karim P. Galzahr · Director
  • Olivier P. Jarry · Director
  • Theodore F. Search · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ceros Financial Services, Inc. (CRD 37869) · Rockville, MarylandSold in all US states

Signed by Christopher P. Acevedo, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 6, 2026. Read the notice at the SEC.

debt, optionsSEC
Jan 2026$4 MPrivate placement after listing$2 to $10 million

OS Therapies Inc: Private sale, Jan 2026

Investors in this round

9 investors had bought by the notice of Jan 20, 2026: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $8 M offered; $4 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$627,550
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher P. Acevedo · Executive Officer · Chief Financial Officer
  • Paul A. Romness · Executive Officer, Director · Chairman, President and Chief Executive Officer
  • Robert G. Petit · Executive Officer · Chief Medical Officer and Chief Scientific Officer
  • Avril P. McKean Dieser · Director
  • John P. Ciccio · Director
  • Karim P. Galzahr · Director
  • Olivier P. Jarry · Director
  • Theodore F. Search · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ceros Financial Services, Inc. (CRD 37869) · Rockville, MarylandSold in all US states

Signed by Christopher P. Acevedo, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 20, 2026. Read the notice at the SEC.

equity, optionsSEC
Sep 2025$4 MPrivate placement after listing$2 to $10 million

OS Therapies Inc: Private sale, Sep 2025

Investors in this round

10 investors had bought by the notice of Sep 10, 2025: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$56,667
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher P. Acevedo · Executive Officer · Chief Financial Officer
  • Paul A. Romness · Executive Officer, Director · Chairman, President and Chief Executive Officer
  • Robert G. Petit · Executive Officer · Chief Medical Officer and Chief Scientific Officer
  • Avril P. McKean Dieser · Director
  • John P. Ciccio · Director
  • Karim P. Galzahr · Director
  • Olivier P. Jarry · Director
  • Theodore F. Search · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ceros Financial Services, Inc. (CRD 37869) · Rockville, MarylandSold in all US states

Signed by Christopher P. Acevedo, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 10, 2025. Read the notice at the SEC.

equity, optionsSEC
Jun 2025$4 MPrivate placement after listing$2 to $10 million

OS Therapies Inc: Private sale, Jun 2025

Investors in this round

27 investors had bought by the notice of Jul 16, 2025: 27 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$210,839
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher P. Acevedo · Executive Officer · Chief Financial Officer
  • Paul A. Romness · Executive Officer, Director · Chairman, President and Chief Executive Officer
  • Robert G. Petit · Executive Officer · Chief Medical Officer and Chief Scientific Officer
  • Avril P. McKean Dieser · Director
  • John P. Ciccio · Director
  • Karim P. Galzahr · Director
  • Olivier P. Jarry · Director
  • Theodore F. Search · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Ceros Financial Services, Inc. (CRD 37869) · Rockville, MarylandSold in all US states

Signed by Christopher P. Acevedo, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 16, 2025. Read the notice at the SEC.

equity, optionsSEC
Dec 2024$7 MNo. 2$2 to $10 million

OS Therapies Inc: Raise no. 2, Dec 2024

Investors in this round

34 investors had bought by the notice of Jan 22, 2025: 34 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $10 M offered; $3 M still to sell
Smallest investment taken
$10,000
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$240,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher P. Acevedo · Executive Officer · Chief Financial Officer
  • Gerald P. Commissiong · Executive Officer · Chief Business Officer
  • Paul A. Romness · Executive Officer, Director · Founder, Chairman, President and Chief Executive Officer
  • Robert G. Petit · Executive Officer · Chief Medical Officer and Chief Scientific Officer
  • Avril P. McKean Dieser · Director
  • John P. Ciccio · Director
  • Olivier R. Jarry · Director
  • Theodore F. Search · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Brookline Capital Markets (CRD 44656) · broker-dealer Arcadia Securities, LLC (CRD 44656) · New York, New YorkSold in AL, CA, FL, GA, ID, IL, LA, MD, MN, NJ, NV, NY, TX, VA, WA, WI, WY
  • Ceros Financial Services, Inc. (CRD 37869) · Rockville, MarylandSold in AL, CA, FL, GA, ID, IL, LA, MD, MN, NJ, NV, NY, TX, VA, WA, WI, WY

Remarks in the notice

  • On the amounts: “After selling $7,103,000 in the Offering, the Issuer has determined to close the Offering.”

Signed by Paul A. Romness, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 22, 2025. Read the notice at the SEC.

equity, optionsSEC
Nov 2022$2 MNo. 1$2 to $10 million

OS Therapies Inc: Raise no. 1, Nov 2022

Investors in this round

11 investors had bought by the notice of Jan 11, 2023: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $2 M offered
Smallest investment taken
$50,000
What was sold
equity, options or other rights to buy securities, other: Convertible promissory notes including underlying Class A common stock issuable upon conversion of such notes.
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christopher Acevedo · Executive Officer · Chief Financial Officer
  • Jutta Wanner · Executive Officer · Chief Technology Officer
  • Paul Romness · Executive Officer, Director · President and Chief Executive Officer
  • Robert Petit · Executive Officer · Chief Scientific Officer and Chief Medical Officer
  • Colin Goddard · Director
  • Joacim Borg · Director
  • John Ciccio · Director
  • Theodore Search · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Noble Capital Markets, Inc. (CRD 15768) · New York, New YorkSold in all US states

Signed by Paul Romness, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 11, 2023. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • OS Therapies Inc chose not to state its revenue in its newest notice of a funding round (Oct 2026).

    SEC Form D · Oct 2026

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Oct 2026

That is all the official record says: OS Therapies Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of OS Therapies Inc are on record.

Investors#

No investor of OS Therapies Inc is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 34 investors.

Largest shareholders today

Institutions holding OS Therapies Incorporated shares, as of Sep 30, 2026.

Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by OS Therapies Inc
NameRoleNamed in
Francis Knuettel IIChief Financial OfficerOct 2026
Kerry ClemChief Commercial OfficerOct 2026
Christopher P. AcevedoChief Financial OfficerAug 2026
Paul A. RomnessChairman, President and Chief Executive OfficerAug 2026
Robert G. PetitChief Medical Officer and Chief Scientific OfficerAug 2026
Gerald P. CommissiongChief Business OfficerJan 2025
Christopher AcevedoChief Financial OfficerJan 2023
Jutta WannerChief Technology OfficerJan 2023
Paul RomnessPresident and Chief Executive OfficerJan 2023
Robert PetitChief Scientific Officer and Chief Medical OfficerJan 2023
Avril McKean DieserDirectorOct 2026
Craig EagleDirectorOct 2026
Olivier JarryDirectorOct 2026
Avril P. McKean DieserDirectorAug 2026
Craig P. EagleDirectorAug 2026
John P. CiccioDirectorAug 2026
Olivier P. JarryDirectorAug 2026
Paul A. RomnessChairman, President and Chief Executive OfficerAug 2026
Theodore F. SearchDirectorAug 2026
Karim P. GalzahrDirectorMar 2026
Olivier R. JarryDirectorJan 2025
Colin GoddardDirectorJan 2023
Joacim BorgDirectorJan 2023
John CiccioDirectorJan 2023
Paul RomnessPresident and Chief Executive OfficerJan 2023
Theodore SearchDirectorJan 2023

Went public since 2024. Its SEC number is that of a company listed on a stock exchange.